NCI, NIH Both Win Increases of 15% in 1999 Budget

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 12
Volume 7
Issue 12

BETHESDA, Md-Congress has appropriated the National Cancer Institute $2.93 billion for fiscal year 1999, which began Oct. 1, up from $2.54 billion in fiscal year 1998. The $390 million funding increase represents a raise of 15.35% for NCI.

BETHESDA, Md—Congress has appropriated the National Cancer Institute $2.93 billion for fiscal year 1999, which began Oct. 1, up from $2.54 billion in fiscal year 1998. The $390 million funding increase represents a raise of 15.35% for NCI.

The House and Senate increased the total NIH budget to $15.65 billion, up from $13.62 billion, a hike of $2.03 billion or 14.9%. Congress passed the appropriations several weeks after the new fiscal year began.

The NCI received 19.2% of the total NIH increase in funding. Much of NCI’s additional budget will go to increase both the number and the dollar amounts of extramural research grants and to expand its clinical trials program.

President Clinton proposed increasing NIH funding by 8.7% in his proposed budget. The House then approved a hike of 9.1%, but the final appropriations figure represented a victory for Senator Arlen Specter (R-Pa), who chairs the Senate appropriations subcommittee that oversees NIH’s budget. Senator Specter is a leading advocate of doubling NIH’s budget over the next 5 years and he had argued throughout the year for a 15% increase for the agency.

An advocacy panel, known as the Research Task Force, has recommended quadrupling the government’s spending for cancer research to $10 billion annually over the next 5 years, and had urged a doubling of the current budget.

The 164-member group said that increasing funding to $10 billion, coupled with the implementation of recommendations it has made, would reduce cancer deaths by 25% to 40% over the next 20 years and eventually save “150,000 to 225,000 lives each year in the US.”

The task force was formed as part of The March, the national effort to make cancer the nation’s number one health priority, and co-chaired by Ellen V. Sigal, PhD, who heads Friends of Cancer Research, and Anna D. Barker, PhD, president and CEO of BIO-NOVA, Inc.

Recent Videos
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
2 experts are featured in this series.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
Related Content